11.06.17
Wayne Froland, Ph.D., has joined Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, as executive vice president of Technical Operations.
Dr. Froland has over 20 years of experience in the industry, with his focus being on process development in biopharmaceutical manufacturing. He was most recently associate vice president at Merck & Co., Inc. where he was responsible for biopharmaceutical product development, commercialization, and manufacturing strategy. Additionally, he has authored 20 peer-reviewed publications in the fields of biochemistry and structural biology.
"Dr. Froland will play an integral role at Symic as we build our capabilities for potential commercial-scale manufacturing," said Ken Horne, Symic Bio's chief executive officer. "His experience with peptide biochemistry will be extremely helpful in satisfying the requirements for production of our novel category of therapeutics targeting the extracellular matrix."
Dr. Froland has over 20 years of experience in the industry, with his focus being on process development in biopharmaceutical manufacturing. He was most recently associate vice president at Merck & Co., Inc. where he was responsible for biopharmaceutical product development, commercialization, and manufacturing strategy. Additionally, he has authored 20 peer-reviewed publications in the fields of biochemistry and structural biology.
"Dr. Froland will play an integral role at Symic as we build our capabilities for potential commercial-scale manufacturing," said Ken Horne, Symic Bio's chief executive officer. "His experience with peptide biochemistry will be extremely helpful in satisfying the requirements for production of our novel category of therapeutics targeting the extracellular matrix."
